Osteoporosis Management

Initial Treatment Approach

The American Academy of Orthopaedic Surgeons recommends immediate fracture management followed by oral bisphosphonate therapy, along with calcium and vitamin D supplementation, for patients with osteoporosis and a recent fragility fracture, with appropriate immobilization of the fracture, pain management with multimodal analgesia, and early mobilization as tolerated to prevent complications of immobility 1
Oral bisphosphonate therapy is the recommended first-line treatment for patients with osteoporosis and a recent fragility fracture, with options including alendronate, risedronate, and ibandronate 2, 3

The American College of Rheumatology recommends oral bisphosphonates as the first-line treatment for osteoporosis, with intravenous bisphosphonates (zoledronic acid) and denosumab as alternative options 3
Denosumab 60 mg subcutaneously every 6 months is particularly beneficial for patients with renal insufficiency 3

Calcium supplementation of 1,000-1,200 mg daily is recommended for patients with osteoporosis 3
Vitamin D supplementation of 600-800 IU daily is recommended, with a target serum level of ≥20 ng/ml 3

Bone mineral density (BMD) testing is recommended to monitor treatment response, with a first follow-up DXA scan 1-2 years after initiating therapy 4
Regular assessment of medication adherence and side effects, as well as periodic reassessment of fracture risk, is necessary to adjust treatment as needed 4

A comprehensive approach to osteoporosis management should include fall prevention strategies, such as home safety assessment and modification, balance and strength training exercises, and review of medications that may increase fall risk 1
Lifestyle modifications, including weight-bearing and resistance exercises, smoking cessation, and limiting alcohol consumption, can also help reduce the risk of subsequent fractures 1

Initial treatment duration of 3-5 years is recommended, with reassessment of fracture risk after this period to determine the need for continued therapy 2
Potential side effects of bisphosphonates, including gastrointestinal issues, atypical femoral fractures, and osteonecrosis of the jaw, should be monitored and addressed as needed 3

Essential laboratory tests should include a comprehensive metabolic panel, complete blood count with differential, and lipid profile, as recommended by Clinical Gastroenterology and Hepatology and Clinical Infectious Diseases 5, 6
The following target values are recommended:
Test Target Value
Total Cholesterol <200 mg/dL
HDL >50 mg/dL
LDL <100 mg/dL
Triglycerides <150 mg/dL
Blood pressure should be measured at every regular healthcare visit, with a target of <120/80 mmHg, and elevated BP defined as 120-129/<80 mmHg, stage 1 hypertension: 130-139/80-89 mmHg, and stage 2 hypertension: ≥140/90 mmHg, as recommended by the American Heart Association 7, 9
Body Mass Index (BMI) should be measured with a target of <25 kg/m², and waist circumference should be measured with a target of <35 inches, as recommended by the American Heart Association 9
Fasting blood glucose or HbA1c should be performed for adults who are overweight (BMI ≥25 kg/m²) or have additional risk factors, with target values: fasting glucose <100 mg/dL or HbA1c <5.7%, and repeat testing at minimum 3-year intervals if results are normal, according to the American Diabetes Association 10, 11, 8, 9

Colorectal cancer screening is recommended beginning at age 50, with options including annual fecal occult blood test (FOBT) or fecal immunochemical test (FIT), flexible sigmoidoscopy every 5 years, colonoscopy every 10 years, or CT colonography every 5 years, as recommended by the American Cancer Society 12, 13, 14, 15
Clinical breast examination is recommended every 3 years for women ages 20-39 and annually for women age 40 and older, with mammography recommended for annual screening beginning at age 40, as recommended by the American Cancer Society 13, 14, 15
Cervical cancer screening should begin approximately 3 years after first vaginal intercourse, but no later than age 21, with a screening frequency of every year with conventional Pap tests or every 2 years using liquid-based Pap tests, and can be stopped for women aged 70+ who have had 3 or more normal Pap tests and no abnormal Pap tests within the last 10 years, as recommended by the American Cancer Society 13
Digital rectal examination (DRE) and prostate-specific antigen (PSA) test should be offered annually beginning at age 50 for men with a life expectancy of at least 10 years, with discussion of potential benefits and limitations of testing before screening, as recommended by the American Cancer Society 13

STI screening, including gonorrhea and chlamydia testing, should be performed annually for sexually active women under 25 or at risk, as recommended by the Clinical Infectious Diseases 6
HIV testing should be performed at least once for all adults, as recommended by the Clinical Infectious Diseases 6
Hepatitis B screening should be performed for adults at high risk, as recommended by the Clinical Infectious Diseases 6

Depression screening should be done using standardized screening tools, as recommended by the Clinical Infectious Diseases and supported by the American Psychiatric Association 6, 16
Bone densitometry should be considered for perimenopausal women with risk factors for premature bone loss, such as low body weight, family history, smoking, or decreased physical activity, as recommended by the Clinical Infectious Diseases and Annals of Internal Medicine 6, 17
Urinalysis should be performed to screen for kidney disease and urinary tract infections, as recommended by the Clinical Infectious Diseases 6
Thyroid stimulating hormone (TSH) levels should be considered for screening, especially with symptoms, as recommended by the Clinical Infectious Diseases 6

For women in perimenopause, laboratory evaluation should include estradiol, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and prolactin, as clinically indicated, to assess menopausal status and rule out other causes of symptoms, according to the National Comprehensive Cancer Network 18
FSH and LH levels are often elevated but not reliable markers of menopausal status in perimenopause, as stated by the National Comprehensive Cancer Network 18
Prolactin levels should be checked to rule out hyperprolactinemia as a cause of menstrual irregularities, as recommended by the National Comprehensive Cancer Network 18
Thyroid function tests (TSH) should be performed to rule out thyroid disease as a cause of symptoms that can mimic perimenopause, according to the National Comprehensive Cancer Network 18
Serial estradiol levels can be useful to determine return of ovarian function in women who have become amenorrheic and later develop bleeding, as stated by the National Comprehensive Cancer Network 18
Anti-Mullerian hormone (AMH) may provide additional information on ovarian status and potentially predict menopause proximity better than FSH or Inhibin B, according to the National Comprehensive Cancer Network 18